Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Erlotinib
Tarceva · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Tarceva (erlotinib HCl) | DRUG | - |
Inclusion Criteria: * Written (signed) informed consent(s) * Inoperable and incurable, locally advanced, recurrent or metastatic NSCLC * Relapse following standard chemotherapy (combination chemotherapy such as two-drug combination chemotherapy, or a single-agent chemotherapy agent for elderly or p...
Top 20 of 76 competitors
Tarceva is used for the treatment of lung cancer, specifically advanced non-small cell lung cancer (NSCLC). It is a small molecule oncology drug that has been studied in Phase 3 clinical trials for this indication.
Tarceva targets kinases, as it belongs to the -tinib class of kinase inhibitors. It works by inhibiting specific kinase enzymes involved in cancer cell growth and proliferation.
Tarceva is developed by Roche Holding AG, a biopharmaceutical company. The company's stock is traded under the ticker symbol RHHBY.
Tarceva is in Phase 3 clinical development for lung cancer. It has completed two Phase 3 trials, with no active trials currently ongoing.
Tarceva has been studied in two completed Phase 3 trials. NCT00047736 evaluated Tarceva with chemotherapy versus chemotherapy alone in advanced lung cancer. NCT00091663 evaluated Tarceva in advanced non-small cell lung cancer, enrolling 5000 patients.
Yes, Tarceva is also known as Erlotinib. Both names refer to the same drug, which is being developed by Roche Holding AG for the treatment of lung cancer.